Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $57.80

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $57.80.

ARCT has been the topic of several recent analyst reports. Wells Fargo & Company cut their price objective on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 10th. Finally, Canaccord Genuity Group decreased their price objective on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th.

Arcturus Therapeutics Stock Down 1.4%

NASDAQ:ARCT traded down $0.17 on Friday, reaching $12.03. 312,120 shares of the company's stock were exchanged, compared to its average volume of 450,879. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $45.00. The firm has a market capitalization of $326.27 million, a price-to-earnings ratio of -5.42 and a beta of 2.36. The business has a fifty day moving average of $11.35 and a 200-day moving average of $14.92.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. The company had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. As a group, equities analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in shares of Arcturus Therapeutics by 0.8% during the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock worth $1,647,000 after buying an additional 742 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after purchasing an additional 883 shares during the last quarter. Tocqueville Asset Management L.P. raised its position in shares of Arcturus Therapeutics by 4.5% during the first quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company's stock worth $248,000 after acquiring an additional 1,000 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 1,132 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Arcturus Therapeutics by 9.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock worth $156,000 after buying an additional 1,232 shares in the last quarter. Institutional investors own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.